Latest Cancer News

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (03-23-2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20 percent of cancers diagnosed worldwide. [...]


Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma (03-22-2017)

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival compared to Velcade (Bortezomib), but also overall improved overall survival, making it a clinically meaningful advance in the treatment of relapsed or refractory [...]


Dealing with Distress (03-17-2017)

Why it’s important to acknowledge distress during cancer care and what to do about it By Teresa L. Deshields and Clorinda Walley The moment a patient is diagnosed with cancer, one symptom is likely to surface: distress. Sadness, fear, helplessness, anger, social concerns, depression, anxiety, panic – just about everyone [...]


Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (03-16-2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination benefits all such women and leads to improved survival without cancer recurrence. The interim [...]


Regional Chemotherapy Technique for Extremity Sarcoma Salvages Patients’ Limbs from Amputation (03-16-2017)

Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option.  However, a technique that limits the application of chemotherapy to the cancerous region can preserve limbs in a high percentage of these patients, researchers [...]


COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma (03-15-2017)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.  The latest data confirm an estimated 45% of patients who received Tafinlar (dabrafenib) + Mekinist (trametinib) combination therapy are alive versus 31% of [...]


Know Your Treatment Options: Colorectal Cancer Liver Metastases (03-13-2017)

Nearly 136,000 Americans are expected to be diagnosed with colorectal (CRC) cancer this year,1 and more than 50% will have their cancer spread to their liver.2  Many individuals with CRC involving the liver erroneously conclude that they have no treatment options other than systemic therapy.  There are however several therapeutic [...]


Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC (03-7-2017)

The US Food and Drug Administration (FDA) granted Priority Review for the expanded use of Zykadia® (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The FDA also granted Breakthrough Therapy designation [...]


New Ovarian Cancer Immunotherapy Study Poses Question: Can Microbiome Influence Treatment Response? (03-6-2017)

A clinical study with Keytruda (pembrolizumab) in a novel untried combination is the first ovarian cancer clinical trial to incorporate gut flora analysis.  Dr. Emese Zsiros, the study’s Principal Investigator, explains a new, unique clinical trial investigating immunotherapy for patients with advanced ovarian cancer. A new clinical study underway at [...]


Proton Beam Therapy may Improve Outcomes for Rectal Cancer (03-6-2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum, pancreatic, or small intestine. This treatment approach is often associated with improved outcomes but [...]


Thyroid Cancer Survivors May Have Increased Risk of Osteoporosis and Heart Conditions (03-3-2017)

The results of a recent new study find that younger survivors of thyroid cancer are at increased risk for osteoporosis, high blood pressure and heart disease.  Thyroid cancer is the fifth most common cancer in women. The thyroid gland is a butterfly-shaped organ that is below the Adam’s apple in [...]


Preliminary Results Suggest That Pamrevlumab is Promising in Pancreatic Cancer (03-2-2017)

Updated results from an ongoing clinical study of pamrevlumab (FG-3019) in combination with standard-of-care chemotherapy in patients with locally advanced pancreatic ductal adenocarcinoma were presented during the ASCO 2017 Gastrointestinal Cancers Symposium in San Francisco and appear to suggest pamrevulmab may improve outcomes compared to chemotherapy alone. About Pancreatic Ductal [...]


Next Page »